Associated Papers
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
Characterisation of pharmacogenomic variation in the Shetland and Orkney Isles in Scotland.
Twesigomwe D et al.
Scientific Reports, 2025
Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L et al.
Pharmacology Research & Perspectives, 2024
Multidisciplinary Insights into the Structure-Function Relationship of the CYP2B6 Active Site.
Angle ED et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity.
Chamorro JG et al.
Pharmacogenetics and Genomics, 2017
Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.
Chelouti H et al.
Annals of Human Biology, 2017
Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.
Heinrich MM et al.
Tuberculosis (edinburgh, Scotland), 2016
Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
Igumnova V et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 2016
Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S et al.
Archives of Toxicology, 2013
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
Gresner P et al.
Lung Cancer (amsterdam, Netherlands), 2007
Select a paper to view details